Shengbin Peng, Youyan Zhang, Xi Lin, Chong Si, Robert Daniel Van Horn, Jack A. Dempsey, Eva Goetz, Robert J. Evans, Andrew Farber, Matthew J. Vandekopple, Wenyu Ming, Hong Gao, Chungping Yu, Wei Guo Xu, Nicholas E. Brown, Michele S. Dowless, Nicholas Pulliam, David A. Barda, Deqi Guo, Serge L. Boulet, Lysian Huber, Andrew Capen, Bonita Jones, Sarah Bogner, Mark A. Castanares, Jennifer Rachelle Stephens, Megan A. Johnson, Carmen L. Curtis, John M. Strelow, Junpeng Xiao, Josh Ballard, Wayne P. Bocchinfuso, Michael J. Chalmers, Jing Wang, Jorg Hendle, Melbert D. Saflor, Danalyn Manglicmot Lagutan, Tarun Gheyi, Anita Sarkar, Margaret Kearins, Frances Tung, Joseph Ho, Logan Rodgers, Jordi Benach, Anton Joseph Frommelt, Lian Zhou, Bradley L. Ackermann, Denis McCann, Anke Klippel, Sean G. Buchanan, James R. Henry, Xueqian Gong. "Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models." Nature Communications, 2026. doi:10.1038/s41467-026-72650-y